Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Dec;8(4):753-62.
doi: 10.1007/s11302-012-9322-7. Epub 2012 Jul 1.

Purinergic system ecto-enzymes participate in the thromboregulation of patients with indeterminate form of Chagas disease

Affiliations

Purinergic system ecto-enzymes participate in the thromboregulation of patients with indeterminate form of Chagas disease

Viviane do Carmo Gonçalves Souza et al. Purinergic Signal. 2012 Dec.

Abstract

Chagas disease (CD) is a chronic and endemic illness caused by the parasite Trypanosoma cruzi. Microvascular disturbances play an important role in the progress of the disease. The purinergic signaling system participates in regulatory functions, such as immunomodulation, neuroprotection, and thromboregulation. This study aimed to investigate the activities of purinergic system ecto-enzymes present on the platelet surface and the platelet aggregation profile from patients with indeterminate form of Chagas disease (IFCD). Thirty patients diagnosed with IFCD and 30 healthy subjects were selected. Ecto-nucleoside triphosphate diphosphohydrolase (E-NTPDase), ecto-nucleotide pyrophosphatase/phosphodiesterase (E-NPP), ecto-5'-nucleotidase (E-5'-NT) and ecto-adenosine deaminase (E-ADA) activities were measured in platelets isolated from these individuals as well as the platelet aggregation. Results demonstrated an increase of 21 % in the E-NPP activity and 30 % in the E-5'-NT activity in IFCD group (P < 0.05); however, a decrease of 34 % in the E-ADA activity was determined in the same group (P < 0.001). A significant decrease of 12.7 % and 12.8 % in the platelet aggregation of IFCD group in two different concentrations of ADP (5 and 10 μM) was observed, respectively (P < 0.05). Increased E-NPP and E-5-NT activities as well as decreased E-ADA activity in platelets of patients with IFCD contributed to decrease platelet aggregation, suggesting that the purinergic system is involved in the thromboregulation process in these patients, since adenosine (the final product of ATP hydrolysis) has cardioprotective and vasodilator effects that prevent the clinical progress of the disease.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
E-NTPDase (ATP and ADP hydrolysis, (a and b), respectively) and E-5′-NT (AMP hydrolysis, (c)) in platelets of patients with indeterminate form of Chagas disease (IFCD). Bars represent means±SEM. The double asterisk symbol represents statistical difference from the control group (Student's t test, P < 0.01, n = 30)
Fig. 2
Fig. 2
E-NPP activity in platelets of patients with indeterminate form of Chagas disease (IFCD). Bars represent means±SEM. The asterisk symbol represents statistical difference from the control group (Student's t test, P < 0.05, n = 30)
Fig. 3
Fig. 3
E-ADA activity in platelets of patients with indeterminate form of Chagas disease (IFCD). Bars represent means±SEM. The three-asterisk symbol represents statistical difference from the control group (Student's t test, P < 0.001, n = 30)
Fig. 4
Fig. 4
Platelet aggregation profile in patients with indeterminate form of Chagas disease (IFCD) and healthy subjects (control). Platelet aggregation was evaluated by using ADP as agonist at concentrations of 5 and 10 μM. The results are expressed as percentage of aggregation. The asterisk symbol represents statistical difference from the control group (Student t test, P < 0.05, n = 15)

Similar articles

Cited by

References

    1. Rossi MA, Bestetti RB. Hipótese unificada sobre a patogênese da cardiopatia chagásica crônica. Implicações terapêuticas. Arq Bras Cardiol. 1995;64:255–260. - PubMed
    1. Prata A. Clinical and epidemiological aspects of Chagas' disease. Lancet Infect Dis. 2001;1:92–100. doi: 10.1016/S1473-3099(01)00065-2. - DOI - PubMed
    1. Prata A. Prognóstico e complicações da doença de Chagas. Rev Goiana Med. 1959;5:87–96.
    1. Gonçalves JG, Dias Silva VJ, Calzada Borges MC, Prata A, Correia D. Mortality indicators among chronic Chagas patients living in an endemic area. Int J Cardiol. 2010;143:235–242. doi: 10.1016/j.ijcard.2009.02.011. - DOI - PubMed
    1. Rossi MA. Microvascular changes as a cause of chronic cardiomyopathy in Chagas' disease. Am Heart J. 1990;120:233–236. doi: 10.1016/0002-8703(90)90191-Y. - DOI - PubMed

Publication types